Stablecoin Development's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Stablecoin Development (SDEV) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Stablecoin Development vs Its Competitors
- TTM: Trailing 12-month revenue of 7M vs 671M combined for its competitors (1.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+18.1% annualized vs trailing 12 months), vs accelerating (+10.7%) for its tracked peer group.
- Growth: Stablecoin Development generated 310.8% revenue growth year over year in Q3 2026, vs 39.6% for its competitors combined.
- Profitability: Its 2,353.4% net margin compares with -22.0% for the peer group.
- Scale: Stablecoin Development ranks #351 of 546 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Stablecoin Development accounted for 1.1% of combined revenue among its tracked peer group, up from 0.4% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
SDEV Sales vs. its Competitors, Q3 2026
Stablecoin Development reported revenue growth of 310.75 % year on year in Q3 2026, above its competitors' combined revenue growth of 39.63 %.
With a net margin of 2,353.41 %, Stablecoin Development achieved higher profitability than its competitors (-21.95 %).
Stablecoin Development generated 1.14 % of the combined sales of its peer group, up from 0.39 % a year earlier.
Stablecoin Development vs. its Competitors, Q3 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Stablecoin Development reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Stablecoin Development and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Stablecoin Development Corporation | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Stablecoin Development's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 310.8% for Stablecoin Development. Stablecoin Development's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Stablecoin Development's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Stablecoin Development Corporation | - | - | - | - |
| Competitors combined (15) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SDEV Stock Performance relative to its Competitors
SDEV Stock Performance relative to High-Confidence Competitors
SDEV Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Liquidia Corporation | 282.9% | Outperformed |
| 2 | Mirum Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Xeris Biopharma Holdings Inc | 282.9% | Outperformed |
| 4 | Belite Bio Inc | 282.9% | Outperformed |
| 5 | Sarepta Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Stablecoin Development's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Stablecoin Development's Comment on Competition and Industry Peers
Publicly Traded Peers of Stablecoin Development Corporation
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Stablecoin Development Corporation |
197.84 | 7.25 |
 Mirum Pharmaceuticals Inc |
6,178.30 | 670.78 |
 Belite Bio Inc |
4,802.33 | - |
 Liquidia Corporation |
4,511.15 | 450.91 |
 Xeris Biopharma Holdings Inc |
2,260.53 | 335.41 |
 Prestige Consumer Healthcare Inc |
2,109.81 | 1,104.96 |
| SUBTOTAL | 24,557.00 | 4,620.94 |
Sign in to see all competitors of Stablecoin Development Corporation.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Stablecoin Development Corporation versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Stablecoin Development's Competitors Named by the Company
Competitive relationships identified from Stablecoin Development reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| L’Oréal Group | Company report | 85% |
| Coty | Company report | 85% |
| The Estée Lauder Companies, Inc. | Company report | 85% |
| Mary Kay, Inc. | Company report | 85% |
| Elizabeth Arden, Inc. | Company report | 85% |
| The Proctor & Gamble Company | Company report | 85% |
| Avon Products, Inc. | Company report | 85% |
| Shiseido | Company report | 85% |
| Avenova | Company report | 85% |
| Shire Plc | Company report | 85% |
| Allergan plc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Stablecoin Development's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Stablecoin Development's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Liquidia Corporation | Single reportable segment 100.00 % |
| Prestige Consumer Healthcare Inc | North American OTC Healthcare 83.92 % |
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
| Ocular Therapeutix Inc | Single Reportable Segment 100.00 % |
| Adverum Biotechnologies Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Stablecoin Development's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Stablecoin Development Corporation | 198 | - | - |
| Mirum Pharmaceuticals Inc | 6,178 | 1,803,167 | -2,429,780 |
| Belite Bio Inc | 4,802 | - | -3,374,391 |
| Liquidia Corporation | 4,511 | 2,087,532 | 641,694 |
| Xeris Biopharma Holdings Inc | 2,261 | 5,160,215 | -220,154 |
| Prestige Consumer Healthcare Inc | 2,110 | 1,938,521 | 712,758 |
| PEERS TOTAL | 24,359 | 1,622,254 | -686,850 |
Sign in to see all peers for Stablecoin Development Corporation.
Stablecoin Development's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Prestige Consumer Healthcare Inc | United States 78.12 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Stablecoin Development's Position in Industry Market Structure
Market-capitalization share and concentration across all 496 companies in Stablecoin Development's industry classification, broader than the peer set above. Market cap in millions of $.Stablecoin Development ranks #351 of 496 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,280,913 | 21.47 % |
| 2 | Johnson and Johnson | 681,032 | 11.41 % |
| 3 | Beone Medicines Ltd | 589,304 | 9.88 % |
| 4 | Abbvie Inc | 528,644 | 8.86 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 351 | Stablecoin Development Corporation | 28 | 0.00 % |
Market cap and industry share for the rest of Stablecoin Development's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-05.
Stablecoin Development's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 346 | Grace Therapeutics Inc | 31 | -41.75 % |
| 347 | Cns Pharmaceuticals Inc | 30 | - |
| 348 | Nextcure Inc | 29 | -42.48 % |
| 349 | Elicio Therapeutics Inc | 29 | -83.39 % |
| 350 | Annovis Bio Inc | 1,234 | 12.3% |
| 351 | Stablecoin Development Corporation | 28 | -83.58 % |
| 352 | Incannex Healthcare Inc | 1,234 | 12.3% |
| 353 | Serina Therapeutics Inc | 1,234 | 12.3% |
| 354 | Bioharvest Sciences Inc | 1,234 | 12.3% |
| 355 | Filana Therapeutics Inc | 1,234 | 12.3% |
| 356 | Beyondspring Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Stablecoin Development's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-05. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Stablecoin Development's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -0.58 % | 37.69 % (avg) | -38.3 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -6.49 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.58 % (avg) | -7.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Stablecoin Development's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (444 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.6x | - |
| EV / EBITDA | 0.4x | 15.9x | -15.5x |
| P/B | -5.5x | 4.3x | -9.8x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | 28.41 % | -9.93 % (avg) | 38.34 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Stablecoin Development's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2014 | 2015 | 2017 | 2018 | 2019 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -49.04 % | 500.00 % | 53.23 % | -31.39 % | -47.24 % | 9.32 % | -28.23 % | - |
| Operating Margin | -4,561.62 % | -479.66 % | -40.10 % | -62.93 % | -142.45 % | -64.22 % | -74.31 % | - |
| Return on Invested Capital | -99.47 % | -496.43 % | -75.76 % | -53.30 % | -106.04 % | -55.46 % | -598.68 % | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Stablecoin Development's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Stablecoin Development falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.2% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Stablecoin Development's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.58 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Stablecoin Development's dedicated Suppliers and Customers pages, not here.
Stablecoin Development's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Stablecoin Development falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Stablecoin Development's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+18.1% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of competitors (60.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Stablecoin Development's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Stablecoin Development Corporation | 7.47 | 8.02 | - |
| Mirum Pharmaceuticals Inc | 1.21 | 2.38 | 4.27 |
| Belite Bio Inc | 35.71 | 50.02 | - |
| Liquidia Corporation | 1.48 | 2.20 | - |
| Xeris Biopharma Holdings Inc | 1.04 | 1.86 | 60.69 |
| Prestige Consumer Healthcare Inc | 0.72 | 3.63 | 0.67 |
Sign in to see all peers for Stablecoin Development Corporation.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Stablecoin Development's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Stablecoin Development Corporation | Q3 2026 | +310.7 % | - |
| Mirum Pharmaceuticals Inc | Q3 2026 | +39.6 % | - |
| Belite Bio Inc | Q4 2025 | - | - |
| Liquidia Corporation | Q2 2026 | +1,842.7 % | - |
| Xeris Biopharma Holdings Inc | Q2 2026 | +28.7 % | - |
| Prestige Consumer Healthcare Inc | Q2 2026 | +6.6 % | -38.0 % |
| PEERS TOTAL | +3.8 % | - |
Sign in to see all peers for Stablecoin Development Corporation.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Stablecoin Development's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Stablecoin Development Corporation | Q3 2026 | - | - |
| Mirum Pharmaceuticals Inc | Q3 2026 | - | +597.9 % |
| Belite Bio Inc | Q4 2025 | - | +102.9 % |
| Liquidia Corporation | Q2 2026 | - | +962.9 % |
| Xeris Biopharma Holdings Inc | Q2 2026 | +5.2 % | - |
| Prestige Consumer Healthcare Inc | Q2 2026 | +18.8 % | +341.9 % |
Sign in to see all peers for Stablecoin Development Corporation.
Stablecoin Development's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Stablecoin Development Corporation | 424.25% | 428.88% | - |
| Mirum Pharmaceuticals Inc | - | - | - |
| Belite Bio Inc | - | - | - |
| Liquidia Corporation | 36.30% | 42.09% | 149.64% |
| Xeris Biopharma Holdings Inc | - | - | - |
| Prestige Consumer Healthcare Inc | 10.90% | 10.06% | 21.77% |
Sign in to see all peers for Stablecoin Development Corporation.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Stablecoin Development's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Stablecoin Development Corporation | - | 27.30 |
| Mirum Pharmaceuticals Inc | - | 9.21 |
| Belite Bio Inc | - | - |
| Liquidia Corporation | 32.01 | 10.00 |
| Xeris Biopharma Holdings Inc | - | 6.74 |
| Prestige Consumer Healthcare Inc | 12.48 | 1.91 |
| PEERS AVERAGE | - | 5.31 |
Sign in to see all peers for Stablecoin Development Corporation.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.